Table 1 |
||||
|
Services offered in the ANC among attending women Asembo/Gem 2005 and 2002. |
||||
|
Asembo 2005 |
Gem 2005 |
Asembo 2002 |
Gem 2002 |
|
|
Services |
n (%) |
n (%) |
n (%) |
n (%) |
|
|
||||
|
Palpation of abdomen |
238/241 (98.8) |
381/384 (99.2) |
290/292 (99.3) |
272/278 (97.8) |
|
Listen to foetal heart rate |
233/241 (96.7) |
377/384 (98.2) |
NA |
NA |
|
Tetanus vaccination |
232/242 (95.9) |
361/382 (94.5) |
282/292 (96.6) |
273/278 (98.2) |
|
Weight measurement |
191/241 (79.3)* |
377/384 (98.2) |
241/293 (82.3)* |
277/278 (99.6) |
|
Iron supplementation |
197/239 (82.4)* |
260/373 (69.7) |
154/289 (53.3) |
149/277 (53.8) |
|
Folic acid supplementation |
167/232 (72.0)* |
170/356 (47.8) |
153/290 (52.8)* |
100/269 (37.2) |
|
SP ≥ 1 dose |
148/240 (61.7)* |
74/373 (19.8) |
58/286 (20.3) |
63/277 (22.7) |
|
SP ≥ 2 doses |
67/237 (28.3)* |
14/370 (3.8) |
22/237 (9.3) |
20/357 (5.6) |
|
Blood pressure measurement |
152/240 (63.3)* |
274/384 (71.4) |
198/292 (67.8) |
187/276 (67.8) |
|
Test haemoglobin level |
72/237 (30.8) |
144/377 (38.2) |
148/286 (51.8) |
138/274 (48.5) |
|
Urine analysis done |
73/240 (30.4)* |
88/383 (23.0) |
59/293 (20.1)* |
30/278 (10.8) |
|
Stool test |
58/240 (24.2)* |
45/384 (11.7) |
50/293 (17.1)* |
22/278 (7.9) |
|
Antihelminth treatment |
30/237 (12.7)* |
15/365 (4.1) |
13/283 (4.6)* |
2/268 (0.8) |
|
Offered test for STD (e.g. syphilis) |
20/232 (8.6) |
45/377 (11.9) |
62/289 (21.5) |
49/277 (17.7) |
|
Offered test for HIV |
26/232 (11.2)* |
139/379 (36.7) |
NA |
NA |
|
Health talk provided |
42/240 (17.5)* |
115/382 (30.1) |
45/289 (15.6) |
35/278 (12.6) |
|
Information provided on: |
||||
|
Danger signs in pregnancy |
25/241 (10.4) |
44/376 (11.7) |
49/291 (16.8) |
33/276 (12.0) |
|
Malaria in pregnancy |
58/241 (24.0) |
83/381 (21.8) |
NA |
NA |
|
Birth plan discussed |
33/241 (13.7)* |
80/380 (21.1) |
NA |
NA |
|
Danger signs during delivery |
17/241 (7.1) |
37/380 (9.7) |
NA |
NA |
|
Danger signs after delivery |
11/240 (4.6) |
33/381 (8.7) |
NA |
NA |
|
Breastfeeding |
36/240 (15.0)* |
85/383 (22.2) |
NA |
NA |
|
Family planning |
18/240 (7.5)* |
97/383 (25.3) |
NA |
NA |
|
|
||||
|
NA: Not Available SP: sulfadoxine-pyrimethamine * p < 0.05 comparing areas in the same survey |
||||
|
Ouma et al. Reproductive Health 2010 7:1 doi:10.1186/1742-4755-7-1 |
||||
